Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

>

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial collagenase for injection) is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's disease and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has options to all indications using XIAFLEX for non-topical formulations. Auxilium's transmucosal film product candidate for the treatment of overactive bladder is in phase I of development. Auxilium has one pain product using its transmucosal film delivery system in pre-clinical development and has rights to seven additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the interpretation of clinical data; the significance of clinical data to Auxilium, the patients suffering from Dupuytren's contracture and the physicians who treat these patients and the degree to which these individuals find the clinical data reported by Auxilium to be compelling; the contribution of the results of CORD I and CORD II, together with all the previous clinical and pre-clinical data, to the Biologics License Application for XIAFLEX for the treatment of Dupuytren's contracture (the "BLA"); the ti
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
(Date:2/26/2015)... Feb. 26, 2015  Mobility Ventures LLC, an AM ... Bank of America (NYSE: BAC ) that ... financing of the revolutionary MV-1 - - the world,s ... ground up to provide safe and comfortable transportation for ... their loan to purchase a new MV-1 vehicle at ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3National Heart Health Month In February 2
... LLC announced today that it has achieved the ... Products Certification for Health Information Line. The accreditation ... nurseline staffed by highly experienced, registered nurses that ... providing immediate clinical support for everyday health issues ...
... England, April 6, 2011 BioWa, Inc. (BioWa) ... they have entered into a license agreement to ... Technology platform for the development of antibody dependent ... OBT intends to use POTELLIGENT® Technology to develop, ...
Cached Medicine Technology:Alere Earns NCQA Health Information Products Certification for Health Information Line 2Oxford BioTherapeutics Licenses BioWa's POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer 2Oxford BioTherapeutics Licenses BioWa's POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer 3
(Date:2/27/2015)... 27, 2015 Insight Accelerator Labs ... advance the development of an in-line urine flow ... is being developed in direct response to current ... accuracy and error margins with potentially grave consequences. ... measurement and provide trending data analysis to signal ...
(Date:2/27/2015)... Ford, Pennsylvania (PRWEB) February 27, 2015 ... the Spring Breast Augmentation Special at his Chadds Ford, ... 13 through May 1, 2015, and will be priced ... to the latest silicone implants, it will include more ... price and $250 worth of free Dysport. , Space ...
(Date:2/27/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is continuing to make its presence known ... Miami area to host Swirl, A Wine Tasting Event ... on Thursday, March 26, 2015. This year’s wine selection ...
(Date:2/27/2015)... Over 440,000 patients die annually as a ... two jumbo jet airplanes crashing each day. Now more than ... an effort to do all they can to stay safe. ... the 17th U.S. Surgeon General, discusses the importance of safer ... to address safety issues to ensure that all our patients ...
(Date:2/27/2015)... Chicago, IL (PRWEB) February 27, 2015 ... Assistant Professor of Biomedical Engineering at Duke University, ... modification for boys and young men with Duchenne ... 18 in Nature Communications, and Gersbach will discuss ... be held March 11-14 in Washington, D.C. , ...
Breaking Medicine News(10 mins):Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 3Health News:Lymphoma Research Foundation Returns to Miami Beach For Exclusive Swirl Wine Tasting Event 2Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:Statement: New MDA-Funded Genetic Therapy Technique Targets DMD 2
... may not necessarily help sales, rather she could actually negatively ... of the product, says a study//. ,Pretty faces are ... But it is not really effective to use them to ... reported the science portal EurekAlert. ,The research by ...
... experience substantially higher rates of injury compared to people ... ,'People who lived in apartments had twice the ... Ronan Lyons, whose study showed that apartment residents had ... and a sixfold increase in poisonings. ,Home ...
... the Indian information technology (IT) sector. This move has come ... BPO firm. // The main aim of the body is tighten ... clients that India is safe for business. A lot of instances ... One such incidence is the arrest of three employees of Mphasis, ...
... with a family history of breast cancer could be allowed ... These new proposals that is due to be discussed by ... inherited forms of breast cancer will be allowed to select ... ,This landmark ruling from the Human Fertilisation and Embryology ...
... that cutting back a few calories from our diet and ... related changes in cells. // ,Scientists from ... eating a little less food and exercising a little more ... and organ damage in rats. ,The discovery, ...
... that de- addiction drug help to combat alcoholism. The US ... drug blocks craving for any sort of drug. The study ... Association. This drug can be made accessible easily to ... addicts. The two drugs that were tested are naltrexone and ...
Cached Medicine News:Health News:Apartment Dwellers Live Dangerously 2Health News:Women With Breast Cancer Can Now USE IVF To Spare Their Daughters 2Health News:Women With Breast Cancer Can Now USE IVF To Spare Their Daughters 3Health News:Cut Calories to Age Gracefully 2Health News:Cut Calories to Age Gracefully 3
LifeStent FlexStar delivery systems offer clinicians multiple methods for stent deployment to accommodate individual preference....
... Tendril ST leads ... pacing leads, designed to ... reliability and flexibility to ... These pre-formed "J leads ...
RV Tracking for 100 % Resynchronization...
O-arm combines the best features of a traditional c-arm with an intra-operative 3D scannerfor unparalleled surgical imaging....
Medicine Products: